 | | Vol. 12.39 – 5 October, 2021 |
| |
|
|
| Researchers showed that deletion of autophagy-inducing kinase unc-51–like autophagy activating kinase 1 (ULK1) reduced growth of cell line and patient-derived xenografted chronic myeloid leukemia cells in mouse models.
[Science Translational Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| MS67 potently and selectively depleted WD40 repeat domain protein 5 (WDR5) and was more effective than WDR5 protein-protein interactions inhibitors in suppressing transcription of WDR5-regulated genes.
[Science Translational Medicine] |
|
|
|
| The authors showed that the efficacy of immune-stimulatory gene therapy was enhanced in mIDH1 gliomas, due to the reprogramming of the myeloid cells’ compartment infiltrating the tumor microenvironment.
[Science Advances] |
|
|
|
| Valine enhanced hematopoietic progenitor cell (HPC) colony formation, replating of human cord blood (CB) HPC-derived colonies, mouse bone marrow (BM) and human CB HPC survival in vitro, and ex vivo expansion of normal mouse BM HSCs and HPCs.
[Leukemia] |
|
|
|
| Investigators developed a zebrafish tet2 mutant through which they showed that tet2 loss led to restricted hematopoietic differentiation combined with a modest upregulation of p53, which was also characteristic of many inherited bone marrow failure syndromes.
[Leukemia] |
|
|
|
| Scientists show that combining TKI treatment with the small-molecule MCL1 inhibitor S63845 exerted strong synergistic antiviability and proapoptotic effects on chronic myeloid leukemia (CML) lines and CD34+ stem/progenitor cells isolated from untreated CML patients in chronic phase.
[Cell Death & Disease] |
|
|
|
| Researchers characterized a zebrafish smu471 mutant with hematopoietic stem/progenitor cell defects and found that sart3 was the causative gene.
[Cell Death & Disease] |
|
|
|
| The authors developed reproducible methods to derive, from human pluripotent stem cells, a population containing monocyte progenitors able to generate functional osteoclast cells. Within this population, they identified cells with monocyte and osteoclast progenitor activity based on CD11b and CD14 expression.
[Blood Advances] |
|
|
|
| In acute myeloid and lymphoblastic leukemia cells, the clinical JAK inhibitors cerdulatinib, ruxolitinib and tofacitinib reduced Schlafen11 (SLFN11) expression, but interferon did not further induce SLFN11 despite phosphorylated STAT1.
[iScience] |
|
|
|
| The novel role of phosphatidylinositol glycan anchor biosynthesis class N (PIGN) as a regulator of the spindle assembly checkpoint was unveiled in leukemic patient cells and cell lines.
[Scientific Reports] |
| |
|
|
| VIALE-C compared the safety and efficacy of venetoclax or placebo plus low-dose cytarabine in patients with untreated acute myeloid leukemia (AML) ineligible for intensive chemotherapy. Investigators presented an additional six months of follow-up of VIALE-C.
[Blood Cancer Journal] |
|
|
|
| Researchers conducted a multicenter, open-label, Phase II, single-arm study of pembrolizumab in patients with DIPSS intermediate 2 or greater primary, post-essential thrombocythemia or post-polycythemia vera myelofibrosis that were ineligible for or were previously treated with ruxolitinib.
[Blood Advances] |
|
|
|
| Scientists evaluated the efficacy and safety of venetoclax plus azacitidine and donor lymphocyte infusion in treating patients with relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
[Annals of Hematology] |
|
|
|
|
| There is a rising incidence of extramedullary multiple myeloma in the era of novel agents, likely a reflection of longer overall survival (OS), with no standard treatment approach. Patients benefit from aggressive chemotherapy-based approaches, but the OS and prognosis remains poor.
[Blood Cancer Journal] |
|
|
|
| The authors discuss single-cell technologies that have rapidly developed over the last years and have already led to a significant impact in the research of myeloproliferative neoplasms.
[Experimental Hematology] |
|
|
|
|
| The US FDA approved brexucabtagene autoleucel for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Efficacy was evaluated in ZUMA-3, a trial that evaluated brexucabtagene autoleucel in adults with relapsed or refractory B-cell precursor ALL.
[US FDA] |
|
|
|
| Senti Bio announced that it has been awarded a Small Business Innovation Research contract to support further development of SENTI-202 for acute myeloid leukemia towards clinical development.
[Senti Bio] |
|
|
|
|
| September 30 – October 1, 2021
Virtual |
|
|
|
|
|
| | The University of Kansas – Kansas City, Kansas, United States |
|
|
|
| | The University of New Mexico – Albuquerque, New Mexico, United States |
|
|
|
| | Moores Cancer Center, UC San Diego – San Diego, California, United States |
|
|
|
| | NHS Blood and Transplant – Oxford, England, United Kingdom |
|
|
|
| | Cellectis – Paris, France |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
